BioPharma Resources

Drug Trial Radar · NCT06843590

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

May 22, 2025

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Feb 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets

Conditions

  • Idiopathic Hypersomnia

Interventions

  • ALKS 2680Drug

    Oral tablet containing ALKS 2680 for daily, oral administration

  • PlaceboDrug

    Oral placebo tablet for daily administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Epworth Sleepiness Scale (ESS) from baseline to Week 8 by dose levelTime frame: Up to 8 weeks

Locations

50 sites in 8 countries. Site status is shown where the registry gives one.

  • Alkermes Investigator Site

    Cullman, Alabama

  • Alkermes Investigator Site

    Phoenix, Arizona

  • Alkermes Investigator Site

    Little Rock, Arkansas

  • Alkermes Investigator Site

    Los Angeles, California

  • Alkermes Investigator Site

    Redwood City, California

  • Alkermes Investigator Site

    San Francisco, California

  • Alkermes Investigational Site

    Boulder, Colorado

  • Alkermes Investigator Site

    Colorado Springs, Colorado

  • Alkermes Investigator Site

    Brandon, Florida

  • Alkermes Investigator Site

    Miami, Florida

  • Alkermes Investigator Site

    Winter Park, Florida

  • Alkermes Investigator Site

    Atlanta, Georgia

  • Alkermes Investigator Site

    Macon, Georgia

  • Alkermes Investigator Site

    Stockbridge, Georgia

  • Alkermes Investigator Site

    Peoria, Illinois

  • Alkermes Investigator Site

    Kansas City, Kansas

  • Alkermes Investigational Site

    Boston, Massachusetts

  • Alkermes Investigator Site

    Lansing, Michigan

  • Alkermes Investigator Site

    Lincoln, Nebraska

  • Alkermes Investigator Site

    Middletown, New Jersey

  • Alkermes Investigator Site

    Denver, North Carolina

  • Alkermes Investigator Site

    Huntersville, North Carolina

  • Alkermes Investigator Site

    Canton, Ohio

  • Alkermes Investigator Site

    Cincinnati, Ohio

  • Alkermes Investigator Site

    Cleveland, Ohio

  • Alkermes Investigator Site

    Danville, Pennsylvania

  • Alkermes Investigator Site

    Philadelphia, Pennsylvania

  • Alkermes Investigator Site

    Wyomissing, Pennsylvania

  • Alkermes Investigator Site

    Columbia, South Carolina

  • Alkermes Investigator Site

    Austin, Texas

  • Alkermes Investigator Site

    San Antonio, Texas

  • Alkermes Investigator Site

    Sugar Land, Texas

  • Alkermes Investigator Site

    Sugarland, Texas

  • Alkermes Investigator Site

    Madison, Wisconsin

  • Alkermes Investigator Site

    Sydney, New South Wales, Australia

  • Alkermes Investigator Site

    Bedford Park, South Australia, Australia

  • Alkermes Investigator Site

    Clayton, Victoria, Australia

  • Alkermes Investigator Site

    Alken, Belgium

  • Alkermes Investigator Site

    Namur, Belgium

  • Alkermes Investigator Site

    Prague, Czechia

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.